Subrat Kumar Acharya

Subrat Kumar Acharya


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2019 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
ADAjay Duseja
Ajay Duseja
SASubrat Kumar Acharya
Subrat Kumar Acharya
MMManu Mehta
Manu Mehta
SCShruti Chhabra
Shruti Chhabra
.S. Shalimar
. Shalimar
YCYogesh K Chawla
Yogesh K Chawla
Objective Pharmacological treatment of non-alcoholic fatty liver disease (NAFLD) is still evolving. Probiotics could be a promising treatment option, but their effectiveness needs to be established. The present study aimed to evaluate the efficacy of a high potency multistrain probiotic in adult patients with NAFLD. Methods Thirty-nine liver biopsy-proven patients with NAFLD were randomised in a double-blind fashion to either lifestyle modifications plus an oral multistrain probiotic (675 billion bacteria daily, n=19) or identical placebo (n=20) for 1 year. Lifestyle modifications included regular exercise for all and control of overweight/obesity (with additional dietary restrictions), hypertension and hyperlipidaemia in those with these risk factors. Primary objective of the study was the histological improvement in NAFLD activity score (NAS) and its components and secondary objectives were improvement in alanine transaminase (ALT) and cytokine profile. Results Thirty (76.9%) out of 39 patients with NAFLD completed the study with 1 year of follow-up. A repeat liver biopsy at 1 year could be done in 10 patients (52.6%) in probiotic group and five patients (25%) in placebo group. In comparison to baseline, hepatocyte ballooning (p=0.036), lobular inflammation (p=0.003) and NAS score (p=0.007) improved significantly at 1 year in the probiotic group. When compared with placebo, the NAS score improved significantly in the probiotic group (p=0.004), along with improvements in hepatocyte ballooning (p=0.05) and hepatic fibrosis (p=0.018). A significant improvement in levels of ALT (p=0.046), leptin (p=0.006), tumour necrosis factor-α (p=0.016) and endotoxins (p=0.017) was observed in probiotic group in comparison to placebo at 1 year. No significant adverse events were reported in the study. Conclusion Patients with NAFLD managed with lifestyle modifications and multistrain probiotic showed significant improvement in liver histology, ALT and cytokines. Trial registration number The clinical trial is registered with CLINICAL TRIAL REGISTRYINDIA (CTRI); http://ctri.nic.in, No. CTRI/2008/091/000074

1 July 2020 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
AAAnil C. Anand
Anil C. Anand
BNBhaskar Nandi
Bhaskar Nandi
SASubrat Kumar Acharya
Subrat Kumar Acharya
AAAnil Arora
Anil Arora
SBSethu Babu
Sethu Babu
MWManav Wadhawan
Manav Wadhawan

1 January 2020 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
AKAshish Kumar
Ashish Kumar
SASubrat Kumar Acharya
Subrat Kumar Acharya
SSShivaram P. Singh
Shivaram P. Singh
AAAnil Arora
Anil Arora
RDRadha K. Dhiman
Radha K. Dhiman
MWManav Wadhawan
Manav Wadhawan

1 September 2013 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
.S. Shalimar
. Shalimar
SASubrat Kumar Acharya
Subrat Kumar Acharya

19 August 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
AKAshish Kumar
Ashish Kumar
SASubrat Kumar Acharya
Subrat Kumar Acharya
SSShivaram P. Singh
Shivaram P. Singh
ADAjay Duseja
Ajay Duseja
KMKaushal Madan
Kaushal Madan
YCYogesh K. Chawla
Yogesh K. Chawla

1 November 2018 in Digestive and Liver Disease
Verified
Journal Article
Closed access
.S. Shalimar
. Shalimar
GRGyanranjan Rout
Gyanranjan Rout
SJShekhar S. Jadaun
Shekhar S. Jadaun
GRGyan Ranjan
Gyan Ranjan
SKSaurabh Kedia
Saurabh Kedia
AKArti Kapil
Arti Kapil